Sector News

Siegfried opens new drug substances R&D center in Evionnaz

November 24, 2024
Life sciences

Zofingen, Switzerland-based contract development and manufacturing organization (CDMO) Siegfried inaugurated its new global research and development (R&D) center for drug substances at its site in Evionnaz, Switzerland. The 4,500 m2 center houses chemical and analytical facilities, laboratories, and technologies such as flow chemistry, advanced distillation and process analytical technology, as well as new office space.

Together with the R&D center in Zofingen, it will offer chemical process R&D and analytical development services for Siegfried’s global drug substances network. With workspaces for over 100 specialists and 40 new jobs created, the R&D center strengthens Siegfried’s development capabilities in phase II and III supporting the company’s Evolve+ strategy, the company said.

Marcel Imwinkelried, CEO of Siegfried, commented: “The new R&D Center in Evionnaz significantly enhances our Drug Substances network and demonstrates our unwavering commitment to providing cutting-edge research and development capabilities for our customers. It will be a key element in driving development excellence as part of our Evolve+ strategy and represents another pivotal step in strengthening our position among the top providers in the CDMO sector.”

Source: chemanager-online.com

comments closed

Related News

December 14, 2024

With green light from European Commission, Novo Holdings’ proposed $16.5B Catalent buyout nears close

Life sciences

As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have said they expect to close before year-end—just received a major vote of confidence from antitrust officials overseas.

December 14, 2024

EuroAPI vaults operating chief into CEO role as it embarks upon ‘new chapter’

Life sciences

With EuroAPI’s restructuring plan underway, the Sanofi spinoff has pulled a new CEO from within its ranks to guide the company’s next chapter. Drug ingredients specialist EuroAPI on Monday said it had accepted the resignations of Ludwig de Mot as CEO and Viviane Monges as chair of the manufacturer’s board.

December 14, 2024

Lonza plans to shed capsules business, simplify operating structure in push to become ‘pure-play’ CDMO

Life sciences

During an investor update Thursday, Lonza unveiled its “One Lonza” restructuring strategy, under which the company will reorganize its CDMO business, reshape its operating model, work to “elevate” manufacturing and engineering and expand its production footprint.

How can we help you?

We're easy to reach